IBDEI0YK ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17174,1,8,0)
 ;;=8^Congenital Factor XI Deficiency
 ;;^UTILITY(U,$J,358.3,17174,2)
 ;;=^27456
 ;;^UTILITY(U,$J,358.3,17175,0)
 ;;=286.3^^111^1076^6
 ;;^UTILITY(U,$J,358.3,17175,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17175,1,1,0)
 ;;=1^286.3
 ;;^UTILITY(U,$J,358.3,17175,1,8,0)
 ;;=8^Congenital Def of Oth Clotting
 ;;^UTILITY(U,$J,358.3,17175,2)
 ;;=^27437
 ;;^UTILITY(U,$J,358.3,17176,0)
 ;;=286.4^^111^1076^28
 ;;^UTILITY(U,$J,358.3,17176,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17176,1,1,0)
 ;;=1^286.4
 ;;^UTILITY(U,$J,358.3,17176,1,8,0)
 ;;=8^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,17176,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,17177,0)
 ;;=286.52^^111^1076^2
 ;;^UTILITY(U,$J,358.3,17177,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17177,1,1,0)
 ;;=1^286.52
 ;;^UTILITY(U,$J,358.3,17177,1,8,0)
 ;;=8^Acquired Hemophilia
 ;;^UTILITY(U,$J,358.3,17177,2)
 ;;=^340502
 ;;^UTILITY(U,$J,358.3,17178,0)
 ;;=286.59^^111^1076^16
 ;;^UTILITY(U,$J,358.3,17178,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17178,1,1,0)
 ;;=1^286.59
 ;;^UTILITY(U,$J,358.3,17178,1,8,0)
 ;;=8^Oth Hemor d/o d/t Anticoagulant
 ;;^UTILITY(U,$J,358.3,17178,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,17179,0)
 ;;=286.6^^111^1076^10
 ;;^UTILITY(U,$J,358.3,17179,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17179,1,1,0)
 ;;=1^286.6
 ;;^UTILITY(U,$J,358.3,17179,1,8,0)
 ;;=8^Defibrination Syndrome
 ;;^UTILITY(U,$J,358.3,17179,2)
 ;;=^35673
 ;;^UTILITY(U,$J,358.3,17180,0)
 ;;=286.7^^111^1076^1
 ;;^UTILITY(U,$J,358.3,17180,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17180,1,1,0)
 ;;=1^286.7
 ;;^UTILITY(U,$J,358.3,17180,1,8,0)
 ;;=8^Acquired Coagulation Factor Def
 ;;^UTILITY(U,$J,358.3,17180,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,17181,0)
 ;;=287.0^^111^1076^3
 ;;^UTILITY(U,$J,358.3,17181,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17181,1,1,0)
 ;;=1^287.0
 ;;^UTILITY(U,$J,358.3,17181,1,8,0)
 ;;=8^Allergic Purpura
 ;;^UTILITY(U,$J,358.3,17181,2)
 ;;=^101365
 ;;^UTILITY(U,$J,358.3,17182,0)
 ;;=287.1^^111^1076^22
 ;;^UTILITY(U,$J,358.3,17182,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17182,1,1,0)
 ;;=1^287.1
 ;;^UTILITY(U,$J,358.3,17182,1,8,0)
 ;;=8^Qualitative Platelet Defects
 ;;^UTILITY(U,$J,358.3,17182,2)
 ;;=^101922
 ;;^UTILITY(U,$J,358.3,17183,0)
 ;;=287.2^^111^1076^17
 ;;^UTILITY(U,$J,358.3,17183,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17183,1,1,0)
 ;;=1^287.2
 ;;^UTILITY(U,$J,358.3,17183,1,8,0)
 ;;=8^Oth Nonthrombocytopenic Purpuras
 ;;^UTILITY(U,$J,358.3,17183,2)
 ;;=^87741
 ;;^UTILITY(U,$J,358.3,17184,0)
 ;;=287.31^^111^1076^13
 ;;^UTILITY(U,$J,358.3,17184,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17184,1,1,0)
 ;;=1^287.31
 ;;^UTILITY(U,$J,358.3,17184,1,8,0)
 ;;=8^Immune Thrombocytopenic Purpura
 ;;^UTILITY(U,$J,358.3,17184,2)
 ;;=^332746
 ;;^UTILITY(U,$J,358.3,17185,0)
 ;;=287.32^^111^1076^11
 ;;^UTILITY(U,$J,358.3,17185,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17185,1,1,0)
 ;;=1^287.32
 ;;^UTILITY(U,$J,358.3,17185,1,8,0)
 ;;=8^Evan's Syndrome
 ;;^UTILITY(U,$J,358.3,17185,2)
 ;;=^332747
 ;;^UTILITY(U,$J,358.3,17186,0)
 ;;=287.41^^111^1076^20
 ;;^UTILITY(U,$J,358.3,17186,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17186,1,1,0)
 ;;=1^287.41
 ;;^UTILITY(U,$J,358.3,17186,1,8,0)
 ;;=8^Posttransfusion Purpura
 ;;^UTILITY(U,$J,358.3,17186,2)
 ;;=^339609
 ;;^UTILITY(U,$J,358.3,17187,0)
 ;;=287.49^^111^1076^18
 ;;^UTILITY(U,$J,358.3,17187,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,17187,1,1,0)
 ;;=1^287.49
 ;;^UTILITY(U,$J,358.3,17187,1,8,0)
 ;;=8^Oth Secondary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,17187,2)
 ;;=^339610
